A roadmap for systematic humanization of a chimeric antigen receptor: preclinical validation of a humanized CD22 scFv as a model

Read full text Summarise with VIRAT
Authors: Narcís Fernández, Paolo Petazzi, Vladimir Mulens‐Arias, Laura García Pérez, Patrizio Panelli, Víctor M Díaz
Cited by: 0
References: 57

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The humanization of chimeric antigen receptor (CAR) T-cell constructs is essential for reducing immunogenicity while preserving optimal antigen-binding affinity. However, this process poses significant challenges, as alterations within the single-chain variable fragments (scFvs) can adversely affect specificity, stability, and functional efficacy. In this study, we presented a structure-guided humanization strategy for the development of CD22-targeted CAR T cells to treat relapsed or refractory B-cell malignancies. Our approach involved rational grafting of murine complementarity-determining regions (CDRs) onto human antibody frameworks, followed by comprehensive in silico and biophysical evaluations to identify and mitigate potential liabilities, including aberrant glycosylation sites and structural instability. The resulting humanized CD22-CAR constructs retained antigen recognition, specificity, and cytotoxic potency comparable with their murine counterparts, as demonstrated in extensive in vitro and in vivo validation studies. Collectively, these findings established a robust, structure-informed humanization pipeline that supports the translation of next-generation CAR-T therapies with reduced immunogenicity and sustained therapeutic efficacy.

Fields of Study & Subjects

CAR-T cell therapy research Monoclonal and Polyclonal Antibodies Research T-cell and B-cell Immunology

Publication details

Journal / source
Experimental Hematology
Volume
159
Pages
105424–105424
Publication date
24 March 2026
Language
EN